血液系统恶性肿瘤患者接种mRNA-1273 SARS-CoV-2疫苗的细胞与体液免疫原性
本研究评估血液系统恶性肿瘤患者接种第二剂mRNA-1273疫苗后1个月的体液与细胞免疫原性。76.3%(184/241)患者产生体液免疫,细胞应答率为79%(184/233)。抗CD20治疗患者体液应答17.5%而细胞应答71.1%,糖皮质激素治疗GVHD患者体液应答77.3%而细胞应答仅52.4%。
要点
- 第二剂mRNA-1273后1个月,76.3%(184/241)患者产生体液免疫,细胞应答率79%(184/233)。
- 低丙种球蛋白血症、淋巴细胞减少、活动性血液病治疗及近6个月抗CD20治疗与体液应答较差相关。
- 年龄>65岁、活动性疾病、淋巴细胞减少及GVHD免疫抑制治疗与细胞应答受损相关。
核心结论
- 血液系统恶性肿瘤患者对SARS-CoV-2 mRNA-1273疫苗的细胞和体液应答高度受抗CD20治疗和免疫抑制治疗等因素影响,这一观察对患者后续管理有启示。
研究设计与样本
- 研究评估血液系统恶性肿瘤患者接种第二剂mRNA-1273疫苗后1个月的体液和细胞免疫原性。
- 抗体滴度采用Elecsys和LIAISON抗SARS-CoV-2 S检测法测定,T细胞应答采用干扰素-γ释放免疫分析技术评估。
主要发现
- 总体76.3%(184/241)患者产生体液免疫,细胞应答率为79%(184/233)。
- 低丙种球蛋白血症、淋巴细胞减少、活动性血液病治疗及近6个月抗CD20治疗与体液应答较差相关。
- 年龄>65岁、活动性疾病、淋巴细胞减少及GVHD免疫抑制治疗与细胞应答受损相关。
- 抗CD20治疗患者体液应答17.5%而细胞应答71.1%,B细胞缺失而T细胞计数保留。
- GVHD免疫抑制治疗患者体液应答77.3%而细胞应答仅52.4%。
临床怎么用
- 原文结论未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent studies have shown a suboptimal humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients diagnosed with hematologic malignancies; however, data about cellular immunogenicity are scarce. The aim of this study was to evaluate both the humoral and cellular immunogenicity 1 month after the second dose of the mRNA-1273 vaccine. Antibody titers were measured by using the Elecsys and LIAISON anti-SARS-CoV-2 S assays, and T-cell response was assessed by using interferon-γ release immunoassay technology. Overall, 76.3% (184 of 241) of patients developed humoral immunity, and the cellular response rate was 79% (184 of 233). Hypogammaglobulinemia, lymphopenia, active hematologic treatment, and anti-CD20 therapy during the previous 6 months were associated with an inferior humoral response. Conversely, age >65 years, active disease, lymphopenia, and immunosuppressive treatment of graft-versus-host disease (GVHD) were associated with an impaired cellular response. A significant dissociation between the humoral and cellular responses was observed in patients treated with anti-CD20 therapy (the humoral response was 17.5%, whereas the cellular response was 71.1%). In these patients, B-cell aplasia was confirmed while T-cell counts were preserved. In contrast, humoral response was observed in 77.3% of patients undergoing immunosuppressive treatment of GVHD, whereas only 52.4% had a cellular response. The cellular and humoral responses to the SARS-CoV-2 mRNA-1273 vaccine in patients with hematologic malignancies are highly influenced by the presence of treatments such as anti-CD20 therapy and immunosuppressive agents. This observation has implications for the further management of these patients.
引用
- Jiménez M, Roldán E, Fernández-Naval C, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022. PMID: 34844263. doi:10.1182/bloodadvances.2021006101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。